{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:14:00Z","timestamp":1793373240689,"version":"4.5.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Biologics play a positive and effective role in the treatment of immune-related dermatoses. However, many other immune-related diseases have also manifested along with biologics treatment. Paradoxical reaction through immune-related dermatoses refer to the new onset or exacerbation of other immune-mediated dermatoses (mainly psoriasis and atopic dermatitis) after biologics treatment of inflammatory dermatoses (mainly psoriasis and atopic dermatitis), such as new atopic dermatitis (AD) in psoriasis (PsO) treatment and new PsO in AD treatment. A common genetic background and Inflammatory pathway are possible pathogenesis. Faced with paradoxical reactions, the choice of therapy needs to be directed toward therapies effective for both diseases, such as Janus kinase (JAK) inhibitors. The Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathway plays an important role in the inflammatory pathway, and has been widely used in the treatment of AD and PsO in recent years. This article focuses on JAK inhibitors such as tofacitinib, baricitinib, ruxolitinib, Abrocitinib, upadacitinib, and deucravacitinib, to explore the possible application in treatment of paradoxical reactions. Common side effects, baseline risk factors and safety use of JAK inhibitors were discussed.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1341632","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T05:12:40Z","timestamp":1708405960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses"],"prefix":"10.3389","volume":"15","author":[{"given":"Yaxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15156","article-title":"Paradoxical eczematous reaction to ixekizumab","volume":"33","author":"Munera-Campos","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12751","article-title":"Atopic-like dermatitis after secukinumab injection: A case report","volume":"32","author":"Burlando","year":"2019","journal-title":"Dermatol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2062281","article-title":"The dark side of the moon: the immune-mediated adverse events of IL-17A\/IL-17R inhibition","volume":"33","author":"Messina","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"B8","article-title":"Prevalence of atopic dermatitis, allergic rhinitis and asthma in Taiwan: a national study 2000 to 2007","volume":"90","author":"Hwang","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.6.681","article-title":"Prevalence of atopic dermatitis in Korea: analysis by using national statistics","volume":"27","author":"Yu","year":"2012","journal-title":"J Korean Med Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: Results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASW.0000547414.38888.8d","article-title":"Diagnosis and management of atopic dermatitis: A review","volume":"31","author":"Maliyar","year":"2018","journal-title":"Adv Skin Wound Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-018-0004-9","article-title":"Atopic dermatitis","volume":"4","author":"Brunello","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2019.1619570","article-title":"Epidemiology of atopic dermatitis in Europe","volume":"8","author":"Kowalska-Ol\u0119dzka","year":"2019","journal-title":"J Drug Assess"},{"key":"B14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"Bmj"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.110300","article-title":"Atopy, autoimmunity, and the T(H)1\/T(H)2 balance","volume":"137","author":"Prahalad","year":"2000","journal-title":"J Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1002\/ski2.29","article-title":"Can atopic eczema and psoriasis coexist? A systematic review and meta-analysis","volume":"1","author":"Cunliffe","year":"2021","journal-title":"Skin Health Dis"},{"key":"B19","first-page":"496","article-title":"[Concomitant psoriasis vulgaris and atopic dermatitis","volume":"40","author":"Welp","year":"1989","journal-title":"A study 1,065 patients psoriasis] Hautarzt"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000246845","article-title":"Psoriasis and eczema are not mutually exclusive diseases","volume":"189","author":"Williams","year":"1994","journal-title":"Dermatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1702147","article-title":"Concomitant atopic dermatitis and psoriasis - a retrospective review","volume":"32","author":"Barry","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000514581","article-title":"Bidirectional association between psoriasis and atopic dermatitis: A nationwide population-based cohort study","volume":"237","author":"Dai","year":"2021","journal-title":"Dermatology"},{"key":"B23","first-page":"37","article-title":"Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology","volume":"32","author":"Simpson","year":"2002","journal-title":"A population-based study using computerized Gen Pract data Clin Exp Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7527859","DOI":"10.1155\/2020\/7527859","article-title":"Atopic dermatitis and psoriasis as overlapping syndromes","volume":"2020","author":"Bozek","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2014.12.004","article-title":"Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms","volume":"96","author":"Baurecht","year":"2015","journal-title":"Am J Hum Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2","article-title":"Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis","volume":"151","author":"Moy","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15345","article-title":"A case of dupilumab-induced reverse psoriasis in a patient with atopic dermatitis","volume":"35","author":"Fan","year":"2022","journal-title":"Dermatol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5070\/D3271156085","article-title":"Off-label uses of TNF-a inhibitors and IL-12\/23 inhibitors in dermatology","volume":"27","author":"Hong","year":"2021","journal-title":"Dermatol Online J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.013","article-title":"Development of psoriasis during treatment with dupilumab: A systematic review","volume":"86","author":"Brumfiel","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.jid.2021.01.022","article-title":"Early and long-term effects of dupilumab treatment on circulating T-cell functions in patients with moderate-to-severe atopic dermatitis","volume":"141","author":"Bakker","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.35","article-title":"Autoimmune-like syndromes during TNF blockade: does infection have a role","volume":"7","author":"Prinz","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i28.4055","article-title":"Differential regulation of JAK\/STAT-signaling in patients with ulcerative colitis and Crohn's disease","volume":"26","author":"Cordes","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-015-0135-z","article-title":"The specific roles of JAK\/STAT signaling pathway in sepsis","volume":"38","author":"Cai","year":"2015","journal-title":"Inflammation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2016.05.007","article-title":"JAK1 takes a FERM hold of type II cytokine receptors","volume":"24","author":"Babon","year":"2016","journal-title":"Structure"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.10.005","article-title":"Crystal structure of a complex of the intracellular domain of interferon \u03bb Receptor 1 (IFNLR1) and the FERM\/SH2 domains of human JAK1","volume":"428","author":"Zhang","year":"2016","journal-title":"J Mol Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.7.3562","article-title":"Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes","volume":"271","author":"Brizzi","year":"1996","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/08977194.2012.660936","article-title":"Biology and significance of the JAK\/STAT signalling pathways","volume":"30","author":"Kiu","year":"2012","journal-title":"Growth Factors"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking Jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00209.x","article-title":"Signaling pathways in Th2 development","volume":"202","author":"Mowen","year":"2004","journal-title":"Immunol Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2013part II: immune cell subsets and therapeutic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03854.x","article-title":"Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor","volume":"42","author":"Molfino","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"Jakstat"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008271107","article-title":"Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling","volume":"107","author":"Rochman","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.2.984","article-title":"IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3","volume":"179","author":"Albanesi","year":"2007","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.43","article-title":"Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6)","volume":"134","author":"Brauweiler","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2022","journal-title":"Allergol Int"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215786","article-title":"JAK-STAT signaling in asthma","volume":"109","author":"Pernis","year":"2002","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: A review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.3325","article-title":"Atopic dermatitis: Tofacitinib, an option for refractory disease","volume":"8","author":"Berbert Ferreira","year":"2020","journal-title":"Clin Case Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jdcr.2021.01.020","article-title":"Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy","volume":"10","author":"Peterson","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.12.016","article-title":"Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor","volume":"4","author":"Morris","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","article-title":"Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials","volume":"22","author":"King","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: A phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1097\/DER.0000000000000725","article-title":"Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib","volume":"32","author":"Simpson","year":"2021","journal-title":"Dermatitis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/e7ayu8","article-title":"JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis","volume":"39","author":"Crispino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0134-y","article-title":"Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota","volume":"19","author":"Tang","year":"2018","journal-title":"Nat Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00904-4","article-title":"Paradoxical reactions to anti-TNF\u03b1 and anti-IL-17 treatment in psoriasis patients: are skin and\/or gut microbiota involved","volume":"13","author":"Jiraskova Zakostelska","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B101","doi-asserted-by":"crossref","first-page":"101606","DOI":"10.1016\/j.bpg.2019.03.002","article-title":"Pharmacology, efficacy and safety of JAK inhibitors in Crohn\u2019s disease","author":"Ma","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000314","article-title":"Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA","volume":"3","author":"Jani","year":"2017","journal-title":"RMD Open"},{"key":"B104","doi-asserted-by":"crossref","first-page":"58","DOI":"10.15171\/jnp.2017.10","article-title":"MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature","volume":"6","author":"G\u00f3is","year":"2017","journal-title":"J Nephropathol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3668-19","article-title":"IgA vasculitis developed as an adverse effect of tofacitinib taken for rheumatoid arthritis","volume":"59","author":"Itoh","year":"2020","journal-title":"Intern Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-021-01248-x","article-title":"[Treatment of rheumatoid arthritis and spondylarthritis with biologics]","volume":"63","author":"Fiehn","year":"2022","journal-title":"Internist (Berl)"},{"key":"B109","first-page":"381","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"2013","author":"Gabay","year":"9877","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"Kubo","year":"2023","journal-title":"Expert Opin Investigational Drugs"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","volume":"76","author":"Keystone","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"B115","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1341632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T05:12:48Z","timestamp":1708405968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1341632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":115,"alternative-id":["10.3389\/fimmu.2024.1341632"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1341632","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"article-number":"1341632"}}